References
cognitive decline
Participant flow of Trial 1. LCPUFAs, long-chain polyunsaturated fatty acids; LZ, lutein and zeaxanthin; MoCA-J, Montreal Cognitive Assessment Japanese version; PPS, per-protocol set; FAS, full analysis set.Changes in the scores of episodic memory function tests during the Trial 1 intervention at week 12 in the subgroup with cognitive decline. Values are adjusted by baseline scores and given as the mean ± SE. White column, placebo (Participant flow of Trial 2. LCPUFAs, long-chain polyunsaturated fatty acids; LZ, lutein and zeaxanthin; MoCA-J, Montreal Cognitive Assessment Japanese version; PPS, per-protocol set; FAS, full analysis set.Changes in the scores of episodic memory function tests during the Trial 2 intervention at week 12 in the subgroup with cognitive decline. Values are adjusted by baseline scores and given as the mean ± SE. White column, placebo (Combined analysis of the changes (Δ-adjusted) in the scores of episodic memory function tests for subgroups with cognitive decline in Trials 1 and 2. (Baseline characteristics of PPS participants in Trial 1.Mean ± SE. Placebo group (Episodic memory tests by group at the baseline and at 12 weeks in Trial 1.Mean ± SE; Placebo (Baseline characteristics of PPS participants in Trial 2.Mean ± SE; Placebo group (Episodic memory tests by group during the intervention in Trial 2.Mean ± SE. Placebo group (